Published September 2026
Spending on pharma commercialization and consulting is expected to nearly double over the next decade, with the global market reaching approximately $78 billion by 2035.
Growth is being driven by increasing complexity across the drug development and commercialization lifecycle, creating greater demand for specialized external expertise. Specialty drugs now account for approximately 39% of pharmacy revenue, up from 15% in 2010, while payors are placing greater emphasis on real-world evidence and demonstrated value.
Several structural tailwinds continue to support the sector:
- Expanding R&D Pipeline: U.S. pharmaceutical R&D spending has increased approximately 65% since 2016, reaching $109 billion in 2025
- Earlier Launch Readiness: Limited post-approval exclusivity is driving earlier and more intensive launch preparation as manufacturers seek to maximize the commercial opportunity
- Biotech Funding Recovery: Venture funding increased to $41 billion in 2025 from $28 billion in 2024, providing additional capital to advance programs toward key development and commercial milestones
- M&A as a Path to Scale: Growing demand for integrated capabilities is encouraging providers to expand service offerings through acquisitions and build broader commercialization platforms
These dynamics have supported sustained M&A activity, with more than 340 add-on acquisitions and 60 private equity platform investments since 2020. Activity has remained strong in 2026, with 53 transactions completed year to date, compared to 44 over the same period in 2025.
To preview the presentation, complete the form below. To access the full presentation, please contact pharmacommercialization@providenthp.com.
